• MedCap Q2 2026 net sales rose 16% to SEK 606.3 million; adjusted EBITA climbed 28% to SEK 124.5 million.
• EBITA margin widened 1.8 percentage points to 20.5%.
• Performance improved across all business areas; organic net sales growth was 7%, with Specialty Pharma weaker as expected.
• Assistive Tech posted net sales of SEK 284.5 million, up 18%, with an adjusted EBITA margin of 28.1%.
• Biopsafe was acquired as a new MedTech platform; net debt/EBITDA stood at 0.4 excluding IFRS 16.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedCap AB published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.